S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
He Is Giving Away Bitcoin (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
The #1 Crypto for 2024 (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Biden’s $374B Giveaway Into This Sector (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
He Is Giving Away Bitcoin (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
The #1 Crypto for 2024 (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Biden’s $374B Giveaway Into This Sector (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
He Is Giving Away Bitcoin (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
The #1 Crypto for 2024 (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Biden’s $374B Giveaway Into This Sector (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
He Is Giving Away Bitcoin (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
The #1 Crypto for 2024 (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Biden’s $374B Giveaway Into This Sector (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
NASDAQ:AZRX

AzurRx BioPharma (AZRX) Stock Price, News & Analysis

→ You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad)
Free AZRX Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$2.65
▼
$2.88
50-Day Range
$2.40
▼
$41.00
52-Week Range
$3.36
▼
$26.30
Volume
38,061 shs
Average Volume
628,703 shs
Market Capitalization
$26.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisCompetitorsSocial Media
AZRX stock logo

About AzurRx BioPharma Stock (NASDAQ:AZRX)

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.

AZRX Stock News Headlines

April 11, 2024 | seekingalpha.com
YS YS Biopharma Co., Ltd.
April 19, 2023 | finance.yahoo.com
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program
April 19, 2024 | InvestorPlace (Ad)
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
January 15, 2023 | marketwatch.com
First Wave BioPharma Shares Jump 21% on FDA Review of Adrulipase IND Filing
September 16, 2022 | seekingalpha.com
FWBI First Wave BioPharma, Inc.
April 30, 2022 | investing.com
First Wave BioPharma Inc (FWBI)
October 1, 2021 | reuters.com
First Wave BioPharma Inc
September 21, 2021 | marketwatch.com
AzurRx BioPharma Changes Name to First Wave BioPharma
April 19, 2024 | InvestorPlace (Ad)
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
September 21, 2021 | finance.yahoo.com
AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today
September 14, 2021 | benzinga.com
AzurRx BioPharma To Acquire First Wave Bio In Transformative $229 Million Deal; Significantly Expands GI and IBD Treatment Pipeline (NASDAQ: AZRX)
September 14, 2021 | msn.com
Why AzurRx BioPharma's Stock Is Trading Higher Today
September 14, 2021 | finance.yahoo.com
AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M
September 14, 2021 | apnews.com
AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave ...
September 14, 2021 | finance.yahoo.com
AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma
September 13, 2021 | finance.yahoo.com
AzurRx BioPharma To Acquire First Wave Bio For $229M
September 13, 2021 | nasdaq.com
AzurRx Announces Acquisition Of First Wave Bio, And Creation Of First Wave BioPharma
September 13, 2021 | finanznachrichten.de
AzurRx BioPharma, Inc.: AzurRx BioPharma Announces Reverse Stock Split
September 13, 2021 | finance.yahoo.com
AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications
September 10, 2021 | finance.yahoo.com
AzurRx BioPharma Announces Reverse Stock Split
September 10, 2021 | apnews.com
AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial ...
September 10, 2021 | nasdaq.com
AzurRx Activates New Clinical Trial Sites In India For Gastrointestinal Infections COVID-19 Study
September 10, 2021 | finance.yahoo.com
AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
September 9, 2021 | markets.businessinsider.com
DMC Recommends AzurRx Continues Gastrointestinal Infections COVID-19 Study
September 9, 2021 | finance.yahoo.com
AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
September 8, 2021 | finance.yahoo.com
AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis
September 7, 2021 | ca.finance.yahoo.com
AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
See More Headlines
Receive AZRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AzurRx BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/18/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AZRX
CUSIP
N/A
CIK
1604191
Web
www.azurrx.com
Phone
(649) 699-7855
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($11.50)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-32,670,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-482.96%
Return on Assets
-258.47%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.33
Quick Ratio
1.33

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.76) per share
Price / Book
-3.82

Miscellaneous

Outstanding Shares
9,326,000
Free Float
8,645,000
Market Cap
$27.05 million
Optionable
Not Optionable
Beta
1.51
A Guide To High-Short-Interest Stocks Cover
A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • James E. Sapirstein
    Chairman, President & Chief Executive Officer
  • Daniel H. Schneiderman
    Chief Financial Officer
  • James E. Pennington
    Chief Medical Officer
  • Tony Baca
    Vice President-Clinical Operations
  • Martin Krusin
    Senior Vice President-Corporate Development

Key Competitors

View All Competitors

AZRX Stock Analysis - Frequently Asked Questions

When did AzurRx BioPharma's stock split?

AzurRx BioPharma shares reverse split before market open on Monday, September 13th 2021. The 1-10 reverse split was announced on Monday, September 13th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 13th 2021. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of AzurRx BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AzurRx BioPharma investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), Gran Tierra Energy (GTE), Cogent Biosciences (UMRX), KushCo (KSHB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI) and Novan (NOVN).

When did AzurRx BioPharma IPO?

AzurRx BioPharma (AZRX) raised $15 million in an initial public offering on Friday, September 9th 2016. The company issued 2,100,000 shares at $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities acted as the underwriters for the IPO.

This page (NASDAQ:AZRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Your Money is Not Safe
American Alternative
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research